Travere Therapeutics(TVTX)
搜索文档
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Newsfilter· 2024-07-09 04:30
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET. A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events- presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We ...
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
ZACKS· 2024-06-24 20:35
Travere Therapeutics (TVTX) shares soared 5.2% in the last trading session to close at $7.31. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 9.6% gain over the past four weeks.The sudden rise in the stock price has likely been driven by the growing optimism of investors regarding Filspari’s (sparsentan) potential to earn increasing revenues for the company. The drug, approved for treating IgA nephropathy, a form of kidney diseas ...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Newsfilter· 2024-06-12 05:00
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 10,500 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan"), but were granted outside of the 2018 Plan and were grant ...
Travere Therapeutics(TVTX) - 2024 Q1 - Earnings Call Transcript
2024-05-07 09:33
Start Time: 16:30 January 1, 0000 5:26 PM ET Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Conference Call May 06, 2024, 16:30 PM ET Company Participants Eric Dube - CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO Bill Rote - SVP of Research & Development Anne Crotteau - IR Conference Call Participants Anupam Rama - JPMorgan Tyler Van Buren - TD Cowan Joseph Schwartz - Leerink Partners Carter Gould - Barclays Jason Zemansky - Bank of America Maury ...
Travere Therapeutics(TVTX) - 2024 Q1 - Quarterly Report
2024-05-07 04:46
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________ FORM 10-Q _________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact name o ...
Travere Therapeutics(TVTX) - 2024 Q1 - Quarterly Results
2024-05-07 04:05
Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.commediarelations@travere.com Travere Therapeutics Reports First Quarter 2024 Financial Results FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511 new patient start forms (PSFs) for FILSPARI in Q1 2024; Total of 1,963 PSFs received since launch Net product sales of FILSPARI ...
Travere Therapeutics(TVTX) - 2023 Q4 - Annual Report
2024-02-20 21:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K ____________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 27-484269 ...
Travere Therapeutics(TVTX) - 2023 Q4 - Earnings Call Transcript
2024-02-16 18:05
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Conference Call February 15, 2024 4:30 PM ET Company Participants Anne Crotteau - Investor Relations Eric Dube - Chief Executive Officer Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer Bill Rote - Senior Vice President of Research & Development Conference Call Participants Joseph Schwartz - Leerink Partners Greg Harrison - Bank of America Anupam Rama - JP Morgan Tyler Van Buren - TD Cow ...
Travere Therapeutics(TVTX) - 2023 Q3 - Earnings Call Transcript
2023-11-08 10:51
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - Vice President-Investor Relations Dr. Eric Dube - Chief Executive Officer Dr. Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer Dr. Bill Rote - Senior Vice President of Research & Development Conference Call Participants Anupam Rama - JP Morgan Maury Raycroft - Jefferies Greg Harrison - Bank of America Vami ...
Travere Therapeutics(TVTX) - 2023 Q3 - Quarterly Report
2023-11-08 06:14
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________ FORM 10-Q _________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact na ...